Merz gains Radiesse wrinkle filler
This article was originally published in The Rose Sheet
Executive Summary
German drug company's $253 mil. acquisition of California-based BioForm Medical, announced Jan. 4, provides it with latter's FDA-approved Radiesse wrinkle filler, rounding out its aesthetic product offering and accentuating its presence in the U.S. Merz's pre-acquisition aesthetic portfolio included dermal fillers Belotero (hyaluronic acid) and Novabel (alginate), both available in Europe and undergoing trials to support U.S. approval. Sales of Mederma anti-scarring creams have helped support the firm's U.S. business (1"The Rose Sheet" July 20, 2009). Made of smooth calcium hydroxylapatite microspheres suspended in a gel and designed to stimulate production of new collagen as a patient's own soft tissue replaces the gel carrier, Radiesse competes against Allergan's Juvederm, Medicis' Restylane and Johnson & Johnson's Evolence, among others. BioForm booked sales of about $66.5 mil. in fiscal 2009. Following completion of the acquisition, which Merz expects in March, the firm will relocate its U.S. aesthetics business to BioForm's San Mateo, Calif., headquarters and the combined operation will be renamed Merz Aesthetics
You may also be interested in...
Mederma Anti-Scarring Targets Stretch Marks With New Cream
Merz Pharmaceuticals is launching its newest Mederma cream with a specific type of scarring in its crosshairs - striae, or stretch marks
Finance Watch: Canaan, Regeneron Reveal New Funds For Start-Ups
Private Company Edition: Regeneron launched a $500m venture fund and Canaan added $100m, bringing the venture firm’s recent total to $1bn-plus. Also, incubators plan to grow over the next decade and in recent financings Avenzo raised $150m and Nvelop launched with $100m.
Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development
Pink Sheet editors discuss Medicare spending projections for the Alzheimer’s treatment Leqembi, Janet Woodcock’s new post-FDA role, and ongoing preparations for new pneumococcal vaccines that will reach the market soon.